Summit Therapeutics PLC (SMMT)
| Market Cap | 559.03M |
| Revenue (ttm) | 22.09M |
| Net Income (ttm) | -50.29M |
| Shares Out | 335.89M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $6.77 |
| Previous Close | $6.97 |
| Change ($) | -0.20 |
| Change (%) | -2.87% |
| Day's Open | 6.98 |
| Day's Range | 6.51 - 7.00 |
| Day's Volume | 138,740 |
| 52-Week Range | 3.14 - 12.30 |
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Summit Therapeutics Inc. (‘Summit,' the ‘Company,' or the ‘Group')
Summit Therapeutics Inc. (‘Summit', the ‘Company' or the ‘Group')
Summit Therapeutics Inc. (“Summit” or the “Company”)
Summit Therapeutics Inc. (‘Summit’, the ‘Company’ or the ‘Group’)
Summit Therapeutics Inc.
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.75, marking a +1.08% move from the previous day.
Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’)
Is (SMMT) Outperforming Other Medical Stocks This Year?
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.48, marking a -0.43% move from the previous day.
Is (SMMT) Outperforming Other Medical Stocks This Year?
Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.11, moving +0.33% from the previous trading session.
Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.68, moving +0.55% from the previous trading session.
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Does Summit Therapeutics PLC (SMMT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to g...
Top Ranked Momentum Stocks to Buy for April 7th
Top Ranked Momentum Stocks to Buy for March 26th
Top Ranked Momentum Stocks to Buy for March 25th
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICT...
Summit Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
As of late, it has definitely been a great time to be an investor Summit Therapeutics.
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
October's R&D day should include new Phase 2 data for the company's lead candidate ridinilazole.
About SMMT
Summit Therapeutics, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; ... [Read more...]
| Industry Biotechnology | Founded 2003 |
| CEO Robert W. Duggan | Employees 70 |
| Stock Exchange NASDAQ | Ticker Symbol SMMT |
Analyst Forecasts
The average 12-month stock price forecast for SMMT is 4.50, which is a decrease of -33.53% from the latest price.